Trial Profile
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Doses of ABI-H2158 in Healthy Volunteers; and the Multiple-Ascending Dose Pharmacokinetics and Pharmacodynamics in Patients With Chronic Hepatitis B Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs ABI-H2158 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 27 Feb 2023 Results assessing safety, pharmacokinetics and antiviral activity of ABI-H2158 in healthy volunteers published in the Journal of Viral Hepatitis
- 29 Aug 2020 Results from phase 1b study of patients with HBeAg-positive chronic hepatitis B infection reporting antiviral activity, PK and safety of ABI-H2158, presented at The International Liver Congress 2020
- 28 Aug 2020 Results presented in an Assembly Biosciences media release.